Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers (SIPHON)

Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients at risk of non-alcoholic fatty liver disease, alcoholic fatty liver disease, with a control group of participants recruited from the general population.

Study Overview

• Status: Recruiting
• Conditions: Fibrosis; Liver Diseases, Alcoholic
• Intervention / Treatment: Diagnostic test: transient elastography; Diagnostic test: Enhanced liver fibrosis test; Diagnostic test: Indirect serum markers of liver fibrosis; Diagnostic test: Direct serum markers of liver fibrosis; Diagnostic test: LiverTRAIL; Diagnostic test: Cytokeratin 18; Diagnostic test: Omics markers

Detailed Description

This protocol describes a prospective screening study at Odense University Hospital, Department of Gastroenterology and Hepatology. The investigators will use liver stiffness measurements with transient elastography to screen 3000 participants from at-risk populations and 3500 participants from the general population for advanced liver fibrosis. At-risk is defined as either (A) a prior or current alcohol overuse (≥21 units/week for men and ≥14 units/week for women) for more than 5 years, or (B) presence of the metabolic syndrome with or without concomitant type 2 diabetes mellitus.

The study goal is to evaluate the aptitude of transient elastography as a screening tool for advanced liver fibrosis, based on analyses of benefit, harm, detection rate, technical applicability and prognostic potential. Secondary aims are to compare novel serum markers of liver fibrosis as potential screening tools against transient elastography: The Enhanced Liver Fibrosis test, neoepitope markers of extracellular matrix turnover, cytokeratin-18 based markers and indirect indices of fibrosis from algorithms combining routine liver blood test. Screened participants with elevated liver stiffness (≥8.0 kiloPascal; estimated 400 participants with alcoholic liver disease, 400 participants with non-alcoholic fatty liver disease and 280 participants from the general population) will be investigated with 2-dimensional shear-wave elastography and abdominal ultrasonography and a liver biopsy to confirm or reject presence of advanced fibrosis.

All participants with a positive screening elastography will be invited for repeated liver stiffness measurements and serum fibrosis markers after a minimum of one year from inclusion.

Participants at risk of alcoholic and non-alcoholic liver disease, independent of liver stiffness measurement at inclusion, will be invited for repeated liver stiffness measurements and serum fibrosis markers after a minimum of one year from inclusion. At-risk participants with elevated liver stiffness measurements at a follow-up visit (>6.0 kiloPascal) will be offered a liver biopsy, however no earlier than two years after the index biopsy.

All participants will be followed for 10 years to assess liver-related outcomes and all-course mortality.

• Study Type: Interventional
• Enrollment (Anticipated): 6500
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Maja Thiele, MD, PhD, Professor; Phone Number: +4524998068; Email: maja.thiele@rsyd.dk

Study Locations

• Denmark
  • Odense, Denmark, 5000
    • Recruiting
    • Department of Gastroenterology and Hepatology, Odense University Hospital
    • Contact: Maja Thiele, MD, PhD; Phone Number: 45 65412752; Email: maja.thiele@rsyd.dk
    • Principal Investigator: Maja Thiele, MD PhD
    • Sub-Investigator: Aleksander Krag, MD PhD Professor

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 28 years to 73 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

INCLUSION CRITERIA

Patients are eligible for screening if the following inclusion criteria are fulfilled:

• Age 30-75 years (except the general population, which should be aged 40-75)
• Informed consent to study investigations
• Ability to read and write Danish AND (only at-risk patients)
• Prior or current alcohol overuse, defined as an average intake of ≥24 grams/day (14 units/week) for women and ≥36 grams/day (21 units/week) for men, for at least 5 years; OR
• Presence of the metabolic syndrome defined by central obesity plus any two of the following four metabolic risk factors: (a) raised triglycerides, (b) reduced HDL cholesterol, (c) raised blood pressure and (d) raised fasting plasma glucose;[38] OR
• Type 2 diabetes mellitus defined by either fasting plasma glucose ≥7 mmol/L, HbA1c ≥48 mmol/mol, a random plasma glucose ≥11.1 mmol/L in the presence of classic diabetes or an oral glucose tolerance test with fasting plasma glucose ≥7.0 mmol/L and/or 2 hour plasma glucose ≥11.1 mmol/L.

EXCLUSION CRITERIA

We will exclude patients from screening in case of:

• Evidence of decompensated liver disease, defined by clinically obvious ascites, overt hepatic encephalopathy, jaundice or large esophageal varices with/without variceal bleeding.
• Known concurrent liver disease other than ALD and NAFLD.
• Cancer or other debilitating disease with an expected survival of less than 12 months.
• Inability to comply with the study protocol.

In screened patients with liver stiffness ≥8 kPa we will abstain from a liver biopsy in case of:

• Contraindications for a percutaneous liver biopsy
• Severe alcoholic hepatitis or other hepatic inflammation evidenced by transaminase elevation of more than three times the upper limit of normal.
• Hepatic congestion or bile duct dilation evidenced by ultrasound.
• Decrease of TE below 6.0 kPa from screening to time of planned liver biopsy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Liver stiffness measurement; Transient elastography in fasting state

Diagnostic test: transient elastography; Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis; Other Names: TE; FibroScan; Diagnostic test: Enhanced liver fibrosis test; Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1); Other Names: ELF; Diagnostic test: Indirect serum markers of liver fibrosis; Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT; Other Names: Forns index; FIB-4; APRI; AST-ALT ratio; Age-platelet ratio; Diagnostic test: Direct serum markers of liver fibrosis; Serum markers that reflect liver extracellular matrix turnover and -accumulation; Other Names: Neoepitopes; Collagen products; Extracellular matrix; Diagnostic test: LiverTRAIL; Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.; Diagnostic test: Cytokeratin 18; Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65); Other Names: CK18; M30; M65; Diagnostic test: Omics markers; Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies; Other Names: Multi-omics markers; Lipidomics; Microbiomics; Genomics; Metagenomics; Metatranscriptomics; Transcriptomics; miRNA-omics; Metabolomics; Proteomics

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Biopsy-verified advanced fibrosis	Number of patients with biopsy-verified, advanced fibrosis (Kleiner fibrosis score ≥F3) detected by screening	5 years
Liver-related outcomes	Number of liver-related clinical outcomes during 10 years of follow up after the first screened patient, compared to a matched, historical control group (The Inter99 study and the Copenhagen and Odense alcohol rehabilitation cohorts). Liver-related outcomes are defined as liver-related death, liver transplant, progression to liver-related complications (ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, jaundice, bleeding from esophagastric varices, hepatocellular carcinoma) or MELD-Na score >15	10 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Liver related outcomes	Number of liver-related clinical outcomes during 10 years of follow up after the first screened patient, compared to a matched, historical control group (The Inter99 study and the Copenhagen and Odense alcohol rehabilitation cohorts). Liver-related outcomes are defined as liver-related death, liver transplant, progression to liver-related complications (ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, jaundice, bleeding from esophagastric varices, hepatocellular carcinoma) or MELD-Na score >15	10 years
Mortality	Overall number of deaths during 10 years of follow up after the first screened patient, compared to a matched, historical control group (The Inter99 study and the Copenhagen and Odense alcohol rehabilitation cohorts).	10 years

Collaborators and Investigators

• Sponsor: Maja Thiele
• Collaborators: University of Oslo; Novo Nordisk A/S; University of Copenhagen; University of Southern Denmark; Steno Diabetes Center Copenhagen; Nordic Bioscience A/S; Biomedical Research Foundation, Academy of Athens; Horizon 2020 - European Commission; Esbjerg University Hospital of South-West Jutland; Odense Municipality Alcohol Rehabilitation Unit; Svendborg Municipality Alcohol Rehabilitation Unit; VLV Bio, Peviva AB; Manatee APS; Siemens Healthcare A/S; European Molecular Biology Laboratory, EMBL, University of Heidelberg
• Investigators: Principal Investigator: Maja Thiele, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Odense University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): October 6, 2017
• Primary Completion (Anticipated): December 30, 2025
• Study Completion (Anticipated): October 30, 2035

Study Registration Dates

• First Submitted: February 4, 2016
• First Submitted That Met QC Criteria: October 11, 2017
• First Posted (Actual): October 13, 2017

Study Record Updates

• Last Update Posted (Actual): September 1, 2022
• Last Update Submitted That Met QC Criteria: August 29, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: collagen; NAFLD; liver fibrosis; screening; microbiome; non-alcoholic fatty liver disease; alcoholic liver disease; metabolomics; fibroscan; elastography; ALD; ultrasound elastography; non-invasive markers; gut-liver-axis; cost-benefit; aixplorer; advanced fibrosis; enhanced liver fibrosis test; direct liver fibrosis markers; ELF; cytokeratin-18; neoepitopes
• Additional Relevant MeSH Terms: Chemically-Induced Disorders; Digestive System Diseases; Pathologic Processes; Alcohol-Related Disorders; Substance-Related Disorders; Alcohol-Induced Disorders; Liver Diseases; Fibrosis; Liver Diseases, Alcoholic; Hematinics; Liver Extracts
• Other Study ID Numbers: S-20170087

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: OPEN - Odense Patient Exploratory data Network, managed by Odense University Hospital
• IPD Sharing Time Frame: After publication of study results
• IPD Sharing Access Criteria: Accessible after contact to OPEN, who will pass on the request to primary investigator. No criteria.
• IPD Sharing Supporting Information Type: Study Protocol; Clinical Study Report (CSR); Analytic Code

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No